Table 1: Demographic and clinical data of study subjects.

PatientAge (y) GenderBP (mm Hg) at admissionHTN* stageChief complaintLaboratory testsConfirmatory tests
SBPDBPSerum K (mEq/L)PAC# (ng/dL)PRA# (ng/mL/h)ARRTTKGTestResult

Control group (n = 9)
150F2301302HTN2.260.080.13462CaptoprilPositive
234F1861052Weakness1.645.800.133524.5Saline loadingPositive
358F2201202HTN2.6929.280.13225CaptoprilPositive
432F1821212HTN2.8740.001.7123
571F146941Weakness2.6132.100.056426.2
659M152711HTN3.4925.550.4557Saline loadingPositive
760F160902Weakness1.74110.700.1861511.9
872M1801172Weakness1.9631.800.06122
956F154831Weakness2.7621.700.53416.1

SPECT/CT group (n = 6)
1055F140901Accidentally palpable Irregular pulse3.2431.92.52138.8Saline loading CaptoprilNegative
1148F145801HTN4.0126.80.06447Saline loading CaptoprilNegative
1257M1701002HTN2.7937.20.3211672.1 mEq/d!Saline loadingNegative
1356M1449014.1425.31.3112
1439M2061152HTN2.227.51.68168.2
1527F150881HTN4.3229.31.6218CaptoprilNegative

Abbreviations: SBP: systolic blood pressure; DBP: diastolic blood pressure; HTN: hypertension; S/S: symptom/sign; K: potassium; PAC: plasma aldosterone concentration; PRA: plasma renin activity; ARR: aldosterone-renin ratio; TTKG: transtubular potassium gradient; F: female; M: male.
#Normal range of PAC, PRA, and serum K is 3.7–24 ng/dL, 0.15–2.33 ng/mL/h, and 3.5 to 5.0 mEq/L, respectively.
*HTN stage according to JNC 7 report.
Patients 12 and 15 had stages 3 and 4 chronic kidney disease with serum creatinine level of 2.2 mg/dL (eGFR 32.9 mL/min/1.73 m2) and 2.5 mg/dL (eGFR 24.6 mL/min/1.73 m2), respectively.
!24-hour urine excretion of potassium.